Review
. 2009 Sep;13(10).
doi: 10.1111/j.1582-4934.2009.00906.x.

Genetic characterization of breast cancer and implications for clinical management

Felipe C Geyer 1 Maria A Lopez-Garcia  Maryou B Lambros  Jorge S Reis-Filho  
Affiliations
  • PMID: 19754664
  •     172 References
  •     7 citations

Abstract

Breast cancer is a genetic disease caused by the accumulation of mutations in neoplastic cells. In the last few years, high-throughput microarray-based molecular analysis has provided increasingly more coherent information about the genetic aberrations in breast cancer. New biomarkers and molecular techniques are slowly becoming part of the diagnostic and prognostic armamentarium available for pathologists and oncologists to tailor the therapy for breast cancer patients. In this review, we will focus on the contribution of breast cancer somatic genetics to our understanding of breast cancer biology and its impact on breast cancer patient management.

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
José Palacios, Emiliano Honrado, +11 authors, Javier Benítez.
Breast Cancer Res Treat, 2005 Mar 17; 90(1). PMID: 15770521
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
A Bergamaschi, E Tagliabue, +10 authors, A-L Børresen-Dale.
J Pathol, 2007 Nov 30; 214(3). PMID: 18044827
Highly Cited.
Stromal gene expression predicts clinical outcome in breast cancer.
Greg Finak, Nicholas Bertos, +9 authors, Morag Park.
Nat Med, 2008 Apr 29; 14(5). PMID: 18438415
Highly Cited.
Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
Tarek M A Abdel-Fatah, Desmond G Powe, +3 authors, Ian O Ellis.
Am J Surg Pathol, 2008 Jan 29; 32(4). PMID: 18223478
The cancer genome.
Michael R Stratton, Peter J Campbell, P Andrew Futreal.
Nature, 2009 Apr 11; 458(7239). PMID: 19360079    Free PMC article.
Highly Cited. Review.
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
Fabrice Andre, Bastien Job, +12 authors, Lajos Pusztai.
Clin Cancer Res, 2009 Jan 17; 15(2). PMID: 19147748
Highly Cited.
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H B Muss, A D Thor, +7 authors, M Barcos.
N Engl J Med, 1994 May 05; 330(18). PMID: 7908410
Highly Cited.
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Ann S Knoop, Helle Knudsen, +9 authors, Danish Breast Cancer Cooperative Group.
J Clin Oncol, 2005 Oct 20; 23(30). PMID: 16234514
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
Scandinavian Breast Group Trial 9401, Minna Tanner, +7 authors, Jonas Bergh.
J Clin Oncol, 2006 May 10; 24(16). PMID: 16682728
WIP1 phosphatase is a negative regulator of NF-kappaB signalling.
Joanne Chew, Subhra Biswas, +9 authors, Vinay Tergaonkar.
Nat Cell Biol, 2009 Apr 21; 11(5). PMID: 19377466
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
S Rayter, R Elliott, +9 authors, A Ashworth.
Oncogene, 2007 Aug 19; 27(8). PMID: 17700519
Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.
S Boulton, S Kyle, B W Durkacz.
Carcinogenesis, 1999 Mar 09; 20(2). PMID: 10069454
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Jason I Herschkowitz, Karl Simin, +23 authors, Charles M Perou.
Genome Biol, 2007 May 12; 8(5). PMID: 17493263    Free PMC article.
Highly Cited.
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
Jorge Sergio Reis-Filho, Pete T Simpson, +15 authors, Alan Ashworth.
Clin Cancer Res, 2006 Nov 24; 12(22). PMID: 17121884
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Laura Orlando, Barbara Del Curto, +10 authors, Marco Colleoni.
Breast, 2008 May 06; 17(5). PMID: 18456496
Hereditary breast cancer: from molecular pathology to tailored therapies.
D S P Tan, C Marchiò, J S Reis-Filho.
J Clin Pathol, 2008 Aug 07; 61(10). PMID: 18682420
Review.
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.
C B Vos, A M Cleton-Jansen, +6 authors, M J van de Vijver.
Br J Cancer, 1997 Jan 01; 76(9). PMID: 9365159    Free PMC article.
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
E A Rakha, T C Putti, +6 authors, I O Ellis.
J Pathol, 2006 Jan 24; 208(4). PMID: 16429394
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event.
I-Tien Yeh, Mathew A Martin, +6 authors, Shelly R Gunn.
Mod Pathol, 2009 May 19; 22(9). PMID: 19448591
E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer?
Anne-Marie Cleton-Jansen.
Breast Cancer Res, 2002 Mar 07; 4(1). PMID: 11879552    Free PMC article.
Review.
ETV6 gene rearrangements in invasive breast carcinoma.
Anne Letessier, Christophe Ginestier, +8 authors, Max Chaffanet.
Genes Chromosomes Cancer, 2005 May 12; 44(1). PMID: 15887243
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Chad A Livasy, Gamze Karaca, +4 authors, Charles M Perou.
Mod Pathol, 2005 Dec 13; 19(2). PMID: 16341146
Highly Cited.
Trastuzumab: triumphs and tribulations.
R Nahta, F J Esteva.
Oncogene, 2007 May 29; 26(25). PMID: 17530017
Highly Cited. Review.
DNA topoisomerases: structure, function, and mechanism.
J J Champoux.
Annu Rev Biochem, 2001 Jun 08; 70. PMID: 11395412
Highly Cited. Review.
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, +13 authors, Charles M Perou.
Clin Cancer Res, 2004 Aug 26; 10(16). PMID: 15328174
Highly Cited.
Breast cancer special types: why bother?
J S Reis-Filho, S R Lakhani.
J Pathol, 2008 Sep 18; 216(4). PMID: 18798222
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Copy number alterations that predict metastatic capability of human breast cancer.
Yi Zhang, John W M Martens, +6 authors, John A Foekens.
Cancer Res, 2009 Apr 02; 69(9). PMID: 19336569
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S Paik, J Bryant, +7 authors, N Wolmark.
J Natl Cancer Inst, 1998 Sep 25; 90(18). PMID: 9747867
ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.
Anne-Marie Cleton-Jansen, Ronald van Eijk, +8 authors, Cees J Cornelisse.
BMC Cancer, 2008 Apr 18; 8. PMID: 18416817    Free PMC article.
Molecular evolution of breast cancer.
Peter T Simpson, Jorge S Reis-Filho, Theodora Gale, Sunil R Lakhani.
J Pathol, 2005 Jan 11; 205(2). PMID: 15641021
Highly Cited. Review.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Laurel A Habel, Steven Shak, +12 authors, Charles P Quesenberry.
Breast Cancer Res, 2006 Jun 02; 8(3). PMID: 16737553    Free PMC article.
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, +21 authors, Joe W Gray.
Cancer Cell, 2006 Dec 13; 10(6). PMID: 17157792
Highly Cited.
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer.
Isabelle Bernard-Pierrot, Nadège Gruel, +7 authors, Olivier Delattre.
Cancer Res, 2008 Sep 02; 68(17). PMID: 18757432
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
Somaia Elbauomy Elsheikh, Andrew R Green, +5 authors, Jorge S Reis-Filho.
Breast Cancer Res, 2007 Apr 03; 9(2). PMID: 17397528    Free PMC article.
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
Antonio C Wolff, M Elizabeth H Hammond, +22 authors, College of American Pathologists.
J Clin Oncol, 2006 Dec 13; 25(1). PMID: 17159189
Highly Cited.
Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?
Hervé Bonnefoi, Craig Underhill, Richard Iggo, David Cameron.
Eur J Cancer, 2009 May 30; 45(10). PMID: 19477634
Review.
The molecular portraits of breast tumors are conserved across microarray platforms.
Zhiyuan Hu, Cheng Fan, +28 authors, Charles M Perou.
BMC Genomics, 2006 Apr 29; 7. PMID: 16643655    Free PMC article.
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J S Reis-Filho, C Westbury, J-Y Pierga.
J Clin Pathol, 2006 Mar 01; 59(3). PMID: 16505270    Free PMC article.
Review.
Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.
S Mook, H Bonnefoi, +7 authors, E J Rutgers.
Eur J Cancer, 2009 Feb 24; 45(7). PMID: 19232484
The prognostic role of a gene signature from tumorigenic breast-cancer cells.
Rui Liu, Xinhao Wang, +7 authors, Michael F Clarke.
N Engl J Med, 2007 Jan 19; 356(3). PMID: 17229949
Highly Cited.
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, +9 authors, Poul H B Sorensen.
Cancer Cell, 2002 Nov 27; 2(5). PMID: 12450792
Highly Cited.
Determination of stromal signatures in breast carcinoma.
Robert B West, Dimitry S A Nuyten, +11 authors, Matt van de Rijn.
PLoS Biol, 2005 May 05; 3(6). PMID: 15869330    Free PMC article.
Evaluation of biological pathways involved in chemotherapy response in breast cancer.
Attila Tordai, Jing Wang, +6 authors, Lajos Pusztai.
Breast Cancer Res, 2008 May 01; 10(2). PMID: 18445275    Free PMC article.
Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.
C Marchiò, M Iravani, +13 authors, J S Reis-Filho.
J Pathol, 2008 May 20; 215(4). PMID: 18484683
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Comparison of prognostic gene expression signatures for breast cancer.
Benjamin Haibe-Kains, Christine Desmedt, +6 authors, Christos Sotiriou.
BMC Genomics, 2008 Aug 23; 9. PMID: 18717985    Free PMC article.
Non-operative breast pathology: lobular neoplasia.
Jorge S Reis-Filho, Sarah E Pinder.
J Clin Pathol, 2006 Dec 22; 60(12). PMID: 17182661    Free PMC article.
Review.
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Pratyaksha Wirapati, Christos Sotiriou, +10 authors, Mauro Delorenzi.
Breast Cancer Res, 2008 Jul 30; 10(4). PMID: 18662380    Free PMC article.
Highly Cited.
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, +7 authors, Thomas Helleday.
Nature, 2005 Apr 15; 434(7035). PMID: 15829966
Highly Cited.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Basal-like breast cancer and the BRCA1 phenotype.
N C Turner, J S Reis-Filho.
Oncogene, 2006 Sep 26; 25(43). PMID: 16998499
Highly Cited. Review.
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
Judith A Gilbert, Matthew P Goetz, +9 authors, Matthew M Ames.
Mol Cancer Ther, 2008 Apr 17; 7(4). PMID: 18413808    Free PMC article.
Chromosome 16 tumor-suppressor genes in breast cancer.
Emad A Rakha, Andrew R Green, +2 authors, Ian O Ellis.
Genes Chromosomes Cancer, 2006 Mar 07; 45(6). PMID: 16518845
Review.
Targeting the DNA repair defect of BRCA tumours.
Nicholas Turner, Andrew Tutt, Alan Ashworth.
Curr Opin Pharmacol, 2005 Jun 16; 5(4). PMID: 15955736
Review.
Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner.
M Fiscella, H Zhang, +6 authors, E Appella.
Proc Natl Acad Sci U S A, 1997 Jun 10; 94(12). PMID: 9177166    Free PMC article.
Highly Cited.
Trastuzumab--mechanism of action and use in clinical practice.
Clifford A Hudis.
N Engl J Med, 2007 Jul 06; 357(1). PMID: 17611206
Highly Cited. Review.
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations.
E Honrado, A Osorio, J Palacios, J Benitez.
Oncogene, 2006 Sep 26; 25(43). PMID: 16998498
Review.
Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis.
Yun Xia, Pat Ongusaha, Sam W Lee, Yih-Cherng Liou.
J Biol Chem, 2009 Apr 28; 284(26). PMID: 19395378    Free PMC article.
Histopathology of BRCA1- and BRCA2-associated breast cancer.
Emiliano Honrado, Javier Benítez, José Palacios.
Crit Rev Oncol Hematol, 2006 Mar 15; 59(1). PMID: 16530420
Review.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, +12 authors, Johann S de Bono.
N Engl J Med, 2009 Jun 26; 361(2). PMID: 19553641
Highly Cited.
Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.
H Fujimoto, N Onishi, +8 authors, Y Minami.
Cell Death Differ, 2005 Nov 29; 13(7). PMID: 16311512
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
David Sarrió, Gema Moreno-Bueno, +6 authors, José Palacios.
Int J Cancer, 2003 Jun 12; 106(2). PMID: 12800196
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.
Sathyavageeswaran Shreeram, Weng Kee Hee, +6 authors, Dmitry V Bulavin.
J Exp Med, 2006 Dec 13; 203(13). PMID: 17158963    Free PMC article.
Basal-like breast cancer: a critical review.
Emad A Rakha, Jorge S Reis-Filho, Ian O Ellis.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487574
Highly Cited. Review.
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Bryan T Hennessy, Ana-Maria Gonzalez-Angulo, +24 authors, Gordon B Mills.
Cancer Res, 2009 May 14; 69(10). PMID: 19435916    Free PMC article.
Highly Cited.
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
Nikita Makretsov, May He, +4 authors, David G Huntsman.
Genes Chromosomes Cancer, 2004 Apr 22; 40(2). PMID: 15101049
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
David G Hicks, Brian J Yoder, +7 authors, Raymond R Tubbs.
Hum Pathol, 2005 May 14; 36(4). PMID: 15891995
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Alessandra Gennari, Maria Pia Sormani, +4 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2007 Dec 27; 100(1). PMID: 18159072
BRCA2-dependent and independent formation of RAD51 nuclear foci.
Madalena Tarsounas, Derek Davies, Stephen C West.
Oncogene, 2003 Feb 28; 22(8). PMID: 12606939
Are triple-negative tumours and basal-like breast cancer synonymous?
Emad A Rakha, David S P Tan, +4 authors, Jorge S Reis-Filho.
Breast Cancer Res, 2008 Feb 19; 9(6). PMID: 18279542    Free PMC article.
Cancer: crossing over to drug resistance.
David M Livingston, Daniel P Silver.
Nature, 2008 Feb 29; 451(7182). PMID: 18305536
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Emad A Rakha, Somaia E Elsheikh, +12 authors, Ian O Ellis.
Clin Cancer Res, 2009 Mar 26; 15(7). PMID: 19318481
Highly Cited.
DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.
Fabrice Andre, Chafika Mazouni, Gabriel N Hortobagyi, Lajos Pusztai.
Biochim Biophys Acta, 2006 Sep 12; 1766(2). PMID: 16962247
Review.
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, +9 authors, Toshiyasu Taniguchi.
Nature, 2008 Feb 12; 451(7182). PMID: 18264087    Free PMC article.
Highly Cited.
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
Alan Ashworth.
J Clin Oncol, 2008 Jul 02; 26(22). PMID: 18591545
Highly Cited. Review.
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Xiao-Jun Ma, Zuncai Wang, +27 authors, Dennis C Sgroi.
Cancer Cell, 2004 Jun 15; 5(6). PMID: 15193263
Highly Cited.
Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, +6 authors, Alan Ashworth.
Nature, 2008 Feb 12; 451(7182). PMID: 18264088
Highly Cited.
Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Rachael Natrajan, Maryou B Lambros, +19 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2009 Mar 26; 15(8). PMID: 19318498
Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes.
J S Reis-Filho, R Natrajan, +7 authors, I O Ellis.
Histopathology, 2008 May 09; 52(7). PMID: 18462362
Refinement of breast cancer classification by molecular characterization of histological special types.
B Weigelt, H M Horlings, +7 authors, J L Peterse.
J Pathol, 2008 Aug 23; 216(2). PMID: 18720457
Highly Cited.
Modelling breast cancer: one size does not fit all.
Tracy Vargo-Gogola, Jeffrey M Rosen.
Nat Rev Cancer, 2007 Aug 28; 7(9). PMID: 17721431
Highly Cited. Review.
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
Tarek M A Abdel-Fatah, Desmond G Powe, +3 authors, Ian O Ellis.
Am J Surg Pathol, 2007 Feb 28; 31(3). PMID: 17325484
Do 'basal-like' breast cancers really exist?
Barry Gusterson.
Nat Rev Cancer, 2009 Jan 10; 9(2). PMID: 19132008
Review.
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
Caterina Marchiò, Maryou B Lambros, +11 authors, Anna Sapino.
J Pathol, 2009 Aug 12; 219(1). PMID: 19670217
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Bas Kreike, Marieke van Kouwenhove, +4 authors, Marc J van de Vijver.
Breast Cancer Res, 2007 Oct 04; 9(5). PMID: 17910759    Free PMC article.
Highly Cited.
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Anna Bergamaschi, Young H Kim, +6 authors, Jonathan R Pollack.
Genes Chromosomes Cancer, 2006 Aug 10; 45(11). PMID: 16897746
Highly Cited.
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, +34 authors, Breast Cancer Linkage Consortium.
Clin Cancer Res, 2005 Jul 22; 11(14). PMID: 16033833
Highly Cited.
Integrated profiling of basal and luminal breast cancers.
José Adélaïde, Pascal Finetti, +13 authors, Max Chaffanet.
Cancer Res, 2007 Dec 20; 67(24). PMID: 18089785
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.
Matt van de Rijn, Charles M Perou, +13 authors, Pat Brown.
Am J Pathol, 2002 Dec 06; 161(6). PMID: 12466114    Free PMC article.
Highly Cited.
Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer.
Mads Thomassen, Qihua Tan, +3 authors, Torben A Kruse.
Clin Cancer Res, 2007 Sep 19; 13(18 Pt 1). PMID: 17875763
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer.
Barry A Gusterson, Douglas T Ross, Victoria J Heath, Torsten Stein.
Breast Cancer Res, 2005 Jul 01; 7(4). PMID: 15987465    Free PMC article.
Review.
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Edurne Arriola, Caterina Marchio, +11 authors, Jorge S Reis-Filho.
Lab Invest, 2008 Mar 12; 88(5). PMID: 18332872
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt.
Histopathology, 2008 Jan 04; 52(1). PMID: 18171422
Highly Cited. Review.
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Yixin Wang, Jan G M Klijn, +11 authors, John A Foekens.
Lancet, 2005 Feb 22; 365(9460). PMID: 15721472
Highly Cited.
Novel patterns of genome rearrangement and their association with survival in breast cancer.
James Hicks, Alexander Krasnitz, +20 authors, Anders Zetterberg.
Genome Res, 2006 Dec 05; 16(12). PMID: 17142309    Free PMC article.
Highly Cited.
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.
Britta Weigelt, Bas Kreike, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2008 Sep 26; 117(2). PMID: 18815879
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
Leah M Prentice, Ashleen Shadeo, +14 authors, David G Huntsman.
Oncogene, 2005 Jul 20; 24(49). PMID: 16027731
Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer.
David S P Tan, Jorge S Reis-Filho.
Pathobiology, 2008 Jun 12; 75(2). PMID: 18544961
Review.
Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Christos Sotiriou, Martine J Piccart.
Nat Rev Cancer, 2007 Jun 23; 7(7). PMID: 17585334
Highly Cited. Review.
A mouse model of basal-like breast carcinoma with metaplastic elements.
A McCarthy, K Savage, +3 authors, A Ashworth.
J Pathol, 2007 Jan 11; 211(4). PMID: 17212342
Breast cancer: origins and evolution.
Kornelia Polyak.
J Clin Invest, 2007 Nov 03; 117(11). PMID: 17975657    Free PMC article.
Highly Cited. Review.
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.
S R Lakhani, J Jacquemier, +38 authors, D F Easton.
J Natl Cancer Inst, 1998 Aug 13; 90(15). PMID: 9701363
Highly Cited.
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.
Dmitry V Bulavin, Crissy Phillips, +5 authors, Albert J Fornace.
Nat Genet, 2004 Mar 03; 36(4). PMID: 14991053
Highly Cited.
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.
Laurent Perreard, Cheng Fan, +18 authors, Philip S Bernard.
Breast Cancer Res, 2006 Apr 22; 8(2). PMID: 16626501    Free PMC article.
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
James D Brenton, Lisa A Carey, Ahmed Ashour Ahmed, Carlos Caldas.
J Clin Oncol, 2005 Sep 08; 23(29). PMID: 16145060
Highly Cited. Review.
Comprehensive profiling of 8p11-12 amplification in breast cancer.
Véronique Gelsi-Boyer, Béatrice Orsetti, +20 authors, Max Chaffanet.
Mol Cancer Res, 2005 Dec 29; 3(12). PMID: 16380503
Metaplastic breast carcinomas are basal-like tumours.
J S Reis-Filho, F Milanezi, +6 authors, F C Schmitt.
Histopathology, 2006 Jul 18; 49(1). PMID: 16842242
Expression of luminal and basal cytokeratins in human breast carcinoma.
Dalia M Abd El-Rehim, Sarah E Pinder, +5 authors, Ian O Ellis.
J Pathol, 2004 May 14; 203(2). PMID: 15141381
Highly Cited.
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, +4 authors, Douglas F Easton.
J Clin Oncol, 2002 May 01; 20(9). PMID: 11981002
Highly Cited.
BRCA1, a potential predictive biomarker in the treatment of breast cancer.
Colin R James, Jennifer E Quinn, +2 authors, D Paul Harkin.
Oncologist, 2007 Feb 14; 12(2). PMID: 17296808
Review.
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.
Xiaoling Liu, Henne Holstege, +9 authors, Jos Jonkers.
Proc Natl Acad Sci U S A, 2007 Jul 13; 104(29). PMID: 17626182    Free PMC article.
Highly Cited.
Bringing DNA repair in tumors into focus.
Christopher J Lord, Alan Ashworth.
Clin Cancer Res, 2009 May 19; 15(10). PMID: 19447863
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, +9 authors, L Norton.
N Engl J Med, 2001 Mar 15; 344(11). PMID: 11248153
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer.
Andrew E Teschendorff, Carlos Caldas.
Breast Cancer Res, 2008 Aug 30; 10(4). PMID: 18755024    Free PMC article.
DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Wonshik Han, Eun-Mi Jung, +10 authors, Dong-Young Noh.
Genes Chromosomes Cancer, 2008 Mar 05; 47(6). PMID: 18314908
Introducing molecular subtyping of breast cancer into the clinic?
Therese Sørlie.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204193
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer.
Zeng Quan Yang, Katie L Streicher, +2 authors, Stephen P Ethier.
Cancer Res, 2006 Dec 21; 66(24). PMID: 17178857
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Rachael Natrajan, Britta Weigelt, +10 authors, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2009 Aug 19; 121(3). PMID: 19688261
Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Bonnie Nannenga, Xiongbin Lu, +5 authors, Lawrence A Donehower.
Mol Carcinog, 2006 May 03; 45(8). PMID: 16652371
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
F P O'Malley, S Chia, +5 authors, K I Pritchard.
J Natl Cancer Inst, 2009 Apr 30; 101(9). PMID: 19401546    Free PMC article.
Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
David A Proia, Bonnie W Nannenga, Lawrence A Donehower, Nancy L Weigel.
J Biol Chem, 2005 Dec 15; 281(11). PMID: 16352595
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Alison M Hosey, Julia J Gorski, +15 authors, D Paul Harkin.
J Natl Cancer Inst, 2007 Nov 15; 99(22). PMID: 18000219    Free PMC article.
A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Xiao-Jun Ma, Ranelle Salunga, +8 authors, Dennis Sgroi.
Clin Cancer Res, 2008 May 03; 14(9). PMID: 18451222
Targeted therapy for cancer using PARP inhibitors.
Christopher J Lord, Alan Ashworth.
Curr Opin Pharmacol, 2008 Jul 23; 8(4). PMID: 18644251
Highly Cited. Review.
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Christos Sotiriou, Pratyaksha Wirapati, +17 authors, Mauro Delorenzi.
J Natl Cancer Inst, 2006 Feb 16; 98(4). PMID: 16478745
Highly Cited.
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
Fabrice Andre, Lajos Pusztai.
Nat Clin Pract Oncol, 2006 Nov 03; 3(11). PMID: 17080180
Review.
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Lyndsay N Harris, Gloria Broadwater, +11 authors, Lynn Dressler.
J Clin Oncol, 2009 May 28; 27(21). PMID: 19470942    Free PMC article.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Edurne Arriola, Socorro Maria Rodriguez-Pinilla, +6 authors, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2007 Jan 30; 106(2). PMID: 17260090
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Grazia Arpino, Valerie J Bardou, Gary M Clark, Richard M Elledge.
Breast Cancer Res, 2004 Apr 16; 6(3). PMID: 15084238    Free PMC article.
Highly Cited.
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Elodie Manié, Anne Vincent-Salomon, +13 authors, Marc-Henri Stern.
Cancer Res, 2009 Jan 17; 69(2). PMID: 19147582
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
Patrick W B Derksen, Xiaoling Liu, +11 authors, Jos Jonkers.
Cancer Cell, 2006 Nov 14; 10(5). PMID: 17097565
Highly Cited.
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Sherene Loi, Benjamin Haibe-Kains, +16 authors, Christos Sotiriou.
BMC Genomics, 2008 May 24; 9. PMID: 18498629    Free PMC article.
Highly Cited.
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.
Suet F Chin, Andrew E Teschendorff, +13 authors, Carlos Caldas.
Genome Biol, 2007 Oct 11; 8(10). PMID: 17925008    Free PMC article.
Highly Cited.
gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation.
C Adriana Bañuelos, Judit P Banáth, +2 authors, Peggy L Olive.
Clin Cancer Res, 2009 Apr 30; 15(10). PMID: 19401347
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, +11 authors, Alan Ashworth.
Nature, 2005 Apr 15; 434(7035). PMID: 15829967
Highly Cited.
BRCA1 dysfunction in sporadic basal-like breast cancer.
N C Turner, J S Reis-Filho, +8 authors, A N Tutt.
Oncogene, 2006 Oct 04; 26(14). PMID: 17016441
Highly Cited.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Charles E Geyer, John Forster, +15 authors, David Cameron.
N Engl J Med, 2006 Dec 29; 355(26). PMID: 17192538
Highly Cited.
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.
Caterina Marchiò, Marjan Iravani, +13 authors, Jorge S Reis-Filho.
J Pathol, 2009 May 30; 218(3). PMID: 19479727
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, +13 authors, Lajos Pusztai.
Clin Cancer Res, 2005 Aug 24; 11(16). PMID: 16115903
Highly Cited.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt, Benjamin Haibe-Kains, +6 authors, Christos Sotiriou.
Clin Cancer Res, 2008 Aug 14; 14(16). PMID: 18698033
Highly Cited.
Nestin is expressed in basal-like and triple negative breast cancers.
S Parry, K Savage, C Marchiò, J S Reis-Filho.
J Clin Pathol, 2008 Jul 22; 61(9). PMID: 18641405
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Lyndsay N Harris, Fanglei You, +12 authors, Eric P Winer.
Clin Cancer Res, 2007 Feb 24; 13(4). PMID: 17317830
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.
Anna V Ivshina, Joshy George, +12 authors, Lance D Miller.
Cancer Res, 2006 Nov 03; 66(21). PMID: 17079448
Highly Cited.
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
T A Järvinen, M Tanner, +2 authors, J Isola.
Genes Chromosomes Cancer, 1999 Sep 01; 26(2). PMID: 10469452
Genomic profile of a secretory breast cancer with an ETV6-NTRK3 duplication.
M B K Lambros, D S P Tan, +7 authors, J S Reis-Filho.
J Clin Pathol, 2009 Jun 30; 62(7). PMID: 19561229
Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice.
Ambreen Abdullah-Sayani, Jolien M Bueno-de-Mesquita, Marc J van de Vijver.
Nat Clin Pract Oncol, 2006 Sep 07; 3(9). PMID: 16955089
Review.
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.
L G Fulford, D F Easton, +4 authors, A Hanby.
Histopathology, 2006 Jul 18; 49(1). PMID: 16842243
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast.
S Droufakou, V Deshmane, +3 authors, I R Hart.
Int J Cancer, 2001 Apr 06; 92(3). PMID: 11291078
A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?
B Haibe-Kains, C Desmedt, C Sotiriou, G Bontempi.
Bioinformatics, 2008 Jul 19; 24(19). PMID: 18635567    Free PMC article.
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Kathleen I Pritchard, Lois E Shepherd, +5 authors, National Cancer Institute of Canada Clinical Trials Group.
N Engl J Med, 2006 May 19; 354(20). PMID: 16707747
Highly Cited.
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, +5 authors, Torsten O Nielsen.
Clin Cancer Res, 2008 Mar 05; 14(5). PMID: 18316557
Highly Cited.
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
Kay Savage, Maryou B K Lambros, +11 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2007 Jan 04; 13(1). PMID: 17200343
How basal are triple-negative breast cancers?
François Bertucci, Pascal Finetti, +4 authors, Daniel Birnbaum.
Int J Cancer, 2008 Apr 10; 123(1). PMID: 18398844
Highly Cited.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators.
N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393
Highly Cited.
The genomic profile of HER2-amplified breast cancers: the influence of ER status.
C Marchiò, R Natrajan, +13 authors, J S Reis-Filho.
J Pathol, 2008 Sep 24; 216(4). PMID: 18810758
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q.
Tom van Wezel, Marcel Lombaerts, +5 authors, Anne-Marie Cleton-Jansen.
Breast Cancer Res, 2005 Nov 11; 7(6). PMID: 16280054    Free PMC article.
Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Felipe Correa Geyer, Jorge Sergio Reis-Filho.
Int J Surg Pathol, 2008 Dec 24; 17(4). PMID: 19103611
Review.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis.
Kay Savage, Samuel Leung, +8 authors, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2007 Oct 04; 110(2). PMID: 17912630
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Xiongbin Lu, Bonnie Nannenga, Lawrence A Donehower.
Genes Dev, 2005 May 05; 19(10). PMID: 15870257    Free PMC article.
Highly Cited.
The molecular genetics of breast cancer: the contribution of comparative genomic hybridization.
Jorge S Reis-Filho, Peter T Simpson, Theodora Gale, Sunil R Lakhani.
Pathol Res Pract, 2005 Dec 06; 201(11). PMID: 16325514
Review.
Next-generation sequencing.
Jorge S Reis-Filho.
Breast Cancer Res, 2010 Jan 20; 11 Suppl 3. PMID: 20030863    Free PMC article.
Transcriptomic landscape of breast cancers through mRNA sequencing.
Jeyanthy Eswaran, Dinesh Cyanam, +7 authors, Rakesh Kumar.
Sci Rep, 2012 Feb 23; 2. PMID: 22355776    Free PMC article.
Involving disparate populations in clinical trials and biobanking protocols: experiences from the community network program centers.
Beti Thompson, James R Hébert.
Cancer Epidemiol Biomarkers Prev, 2014 Mar 13; 23(3). PMID: 24609845    Free PMC article.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Review.
The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.
Michaela Aubele, Manfred Schmitt, +8 authors, Marion Kiechle.
Dis Markers, 2017 Nov 16; 2017. PMID: 29138528    Free PMC article.
Review.
Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis.
Xiaoguang Lyu, Jiming Hu, Weiguo Dong, Xin Xu.
JMIR Med Inform, 2020 Feb 06; 8(2). PMID: 32014844    Free PMC article.
The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer.
Vanessa Barriga, Nyanbol Kuol, Kulmira Nurgali, Vasso Apostolopoulos.
Cancers (Basel), 2019 Aug 23; 11(8). PMID: 31430935    Free PMC article.